personalized medicinepersonalizedmedicine.partners.org/assets/documents... · personalized...

Conference Program

Personalized Medicine: A Call for Action

A Conference Hosted By

HARVARD MEDICAL SCHOOL – PARTNERS HEALTHCARECENTER FOR GENETICS AND GENOMICS

HARVARD BUSINESSSCHOOL

A CONFERENCE TO DEVELOP STRATEGIES

FOR ACCELERATING THE ADOPTION

OF PERSONALIZED MEDICINE

November 29-30, 2007Joseph B. Martin Conference Center at Harvard Medical School, Boston

HIGHLIGHTS FROM PAST CONFERENCES

3

November 29, 2007

Dear Colleague,

It is my pleasure to welcome you to Personalized Medicine: A Callfor Action. The Harvard Medical School-Partners HealthCareCenter for Genetics and Genomics (HPCGG) is again delighted tocollaborate with Harvard Business School to present a conference to develop strategies for accelerating the adoption of personalizedmedicine. This partnership is important because we believe thatcollaboration between medicine and business is critical for theimplementation of personalized medicine. I am pleased that we arealso continuing our collaboration with the Personalized MedicineCoalition (PMC), an international organization that is doing much

to educate and promote personalized medicine through public discourse about policyissues, which is also essential in working to meet our goal. The PMC is presenting itsThird Annual Award for Leadership in Personalized Medicine at our conference.

Personalized medicine is made possible by three recent revolutions in Genetics. The firstis the recognition that genetics plays a very important role in virtually all aspects ofhuman health and disease. The second is the Human Genome Project that provided thesequence of the human and many other genomes and spurred the development of manytools and approaches for high throughput biology. The third revolution is the use ofrapidly accumulating new genetic and genomic knowledge in the care of patients. The transformation of patient care as a result of personalized medicine provides greatopportunities for pharmaceutical, diagnostic and information technology companies, aswell as healthcare providers, payors and regulatory agencies, the physicians who usegenetic knowledge and ultimately the entire human population. The possibilities forreducing suffering, restoring quality of life and facilitating the delivery of cost effectivehealthcare are almost boundless, and our call for action is to accelerate the realization of these goals.

HPCGG aspires to accelerate the promise of personalized medicine by discovering andintegrating genetic knowledge into the practice of healthcare. This conference providesthe forum for continuing discussions to help us reach that goal. I would like to take thisopportunity to thank the members of our organizing committee for their hard work inplanning this conference; our speakers and participants for their enthusiasm in sharingtheir thoughts and plans; and the program’s sponsors whose support enabled this year’sconference. This is truly an exciting time for these discussions and I am delighted youhave decided to join us.

Sincerely,

Raju Kucherlapati, Ph.D.Scientific DirectorHarvard Medical School-Partners HealthCare Center for Genetics and GenomicsPaul C. Cabot Professor of Genetics and Professor of MedicineHarvard Medical School

H A R V A R D M E D I C A L S C H O O L - P A R T N E R S H E A L T H C A R E

C E N T E R F O R G E N E T I C S A N D G E N O M I C S

4

SponsorsThis conference is organized by the Harvard Medical School - Partners Healthcare Center for Genetics and Genomics and Harvard Business School in collaboration

with the Personalized Medicine Coalition. It is made possible by the generous support of our sponsors.

PLATINUM

GOLD

SILVER

BRONZE

CONFERENCE SPONSOR

an Applera Corporation Business

5

Raju Kucherlapati, Ph.D., ChairScientific DirectorHarvard-Partners Center for Genetics and GenomicsPaul C. Cabot Professor of GeneticsProfessor of MedicineHarvard Medical School

Edward Abrahams, Ph.D.Executive DirectorPersonalized Medicine Coalition

Joanne C. Armstrong, M.D.Senior Medical Director for Women'sHealth and Clinical Lead for GenomicsAetna, Inc.

Mara G. AspinallPresident, Genzyme GeneticsGenzyme Corporation

M. Kathleen Behrens, Ph.D.General Partner, RS InvestmentsMember, President’s Council of Advisorson Science and Technology (PCAST)

Nadine Cohen, Ph.D.Head of Pharmacogenomics and SeniorResearch FellowJohnson & Johnson PharmaceuticalResearch and Development, East Coastand Europe

Peter DworkinVice PresidentInvestor Relations and CorporateCommunicationsApplera Corporation

Richard G. Hamermesh, D.B.A.MBA Class of 1961 Professor ofManagement PracticeFaculty Chair, HBS Healthcare InitiativeHarvard Business School

Regina E. Herzlinger, D.B.A.Nancy R. McPherson Professor ofBusiness AdministrationHarvard Business School

Marcia A. KeanChief Executive OfficerFeinstein Kean Healthcare

Jeffrey D. MillerVice PresidentWW Health and Life Sciences,WW Public SectorHewlett-Packard Company

Daniel K. Podolsky, M.D.Chief Academic OfficerPartners HealthCare System, Inc.Mallinckrodt Professor of MedicineHarvard Medical School

Eiry W. Roberts, M.D.Vice President, Project/Program MedicalEli Lilly and Company

Hakan Sakul, Ph.D.Senior Director and Global Head ofDiagnosticsTranslational and Molecular Medicine GroupWorldwide DevelopmentPfizer Global R&D

Rick SchlesingerDirectorMcKinsey & Company

Christine Seidman, M.D.Investigator, Howard Hughes MedicalInstituteThomas W. Smith Professor of Medicine and GeneticsHarvard Medical SchoolDirector, Cardiovascular Genetics CenterBrigham and Women's Hospital

COMMITTEE MEMBERS EX OFFICIO

Rebecca RehmHarvard-Partners Center for Genetics andGenomics

Janice LarsonHarvard-Partners Center for Genetics and Genomics

ORGANIZATIONAL LEADERSHIP

James J. Mongan, M.D.President and Chief Executive OfficerPartners HealthCare System, Inc.

Jeffrey S. Flier, M.D.Dean of the Faculty of MedicineGeorge C. Resiman Professor ofMedicineHarvard Medical School

Jay O. LightDean, Harvard Business School

Conference Organizing Committee

Harvard-Partners Center forGenetics and GenomicsLabs at 65 LandsdowneStreet, Cambridge



6

Conference Program

Thursday, November 29, 2007

Morning Session - Amphitheater

TIME TOPIC SPEAKER / MODERATOR7:30-8:15 Registration &

Continental Breakfast

8:15 Welcome Raju Kucherlapati, Ph.D.Scientific Director, Harvard-Partners Center for Genetics and Genomics, Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School, Boston, MA

8:25 Public Policy Implications of Keynote Speaker: M. Kathleen Behrens, Ph.D.Personalized Medicine General Partner, Consultant, RS Investments, Member,

President’s Council of Advisors on Science and Technology (PCAST), Ross, CA

Introduction by: Mark J. LevinPartner, Third Rock Ventures, LLC, Boston, MA

9:10 The Personalized Health Care Keynote Speaker: Michael O. LeavittChallenge Secretary of Health and Human Services, U.S. Department of

Health and Human Services, Washington, DC

Introduction by: James J. Mongan, M.D.President and Chief Executive Officer, Partners HealthCare,Boston, MA

10:00 Break

10:45-12:15 Session I: Perspectives from Moderator: Richard G. Hamermesh, D.B.A.Pharmaceutical and MBA Class of 1961 Professor of Management Practice,Diagnostics Companies Faculty Chair, HBS Healthcare Initiative,

Harvard Business School, Cambridge, MA

The adoption of personalized medicine is, in part, dependent on the attitudes and approaches that are used by the drugdevelopers, whether they are pharmaceutical companies or biotechnology companies. Companies that pursue diagnostictools or services are also critical players since diagnostics lies at the core of personalized medicine. New drug developmentmay also involve collaborations between drug makers and diagnostics companies. This session will explore the successesand obstacles faced by these industries and their perspectives on actions needed for personalized medicine to become ahealthcare norm.

Garry Neil, M.D., Corporate Vice President, Corporate Office of Science & Technology, Johnson & Johnson, Raritan, NJSamuel Broder, M.D., Chief Medical Officer, Celera, Rockville, MD Peer M. Schatz, Chief Executive Officer, Qiagen, Hilden, GermanyThomas J. Miller, Member, Executive Management Board, Siemens Medical Solutions, Erlangen, Germany

Panel Discussion All Four Speakers

Luncheon & PMC Award Presentation – Rotunda & HIM Room

12:15 Personalized Medicine Coalition’s Third Annual Award for Leadership in Personalized MedicineProspective Medicine: The Next Health Care Transformation

Award Recipient: Ralph Snyderman, M.D.Chancellor Emeritus, Duke University, Founder, Proventys, Inc., Durham, NC

Presentation by: Mara G. AspinallPresident, Genzyme Genetics, Genzyme Corporation, Westborough, MA

Introduction by: Edward Abrahams, Ph.D.Executive Director, Personalized Medicine Coalition, Washington, DC

7

Afternoon Session - Amphitheater

TIME TOPIC SPEAKER / MODERATOR2:15 Markets of One: The Pharmaceutical Keynote Speaker: John C. Lechleiter, Ph.D.

Industry and the Pursuit of President and Chief Operating Officer, Eli Lilly and Company,Personalized Medicine Indianapolis, IN

Introduction by: Deborah Dunsire, M.D.President and CEO, Millennium Pharmaceuticals, Inc.,Cambridge, MA

3:00 Break

3:30-5:00 Session II: Personalized Medicine: Moderator: Christine Seidman, M.D.Clinical and Regulatory Issues Investigator, Howard Hughes Medical Institute, Thomas W.

Smith Professor of Medicine and Genetics, Harvard Medical School, Director, Cardiovascular Genetics Center, Brigham and Women’s Hospital, Boston, MA

It is well known that all drugs are not effective, at least to the same degree, in all of the patients that are treated with them.There are several examples where it is clear that individual genetic variation, with which each person is born, or acquiredgenetic differences, as in the cases of most cancers, are critical to finding the right drug or the right dose of the drug foreach patient. This understanding presents perils and opportunities to drug developers. Some would argue that developmentof targeted therapies would segment the markets and others argue that mechanism- or genetic/genomic- based treatmentwould expand indications for drugs. If new information about the safety or efficacy of drugs based on genes becomes avail-able, it is important to show that gene based clinical decision making would result in better outcomes for patients. Suchinformation gathering is the responsibility of drug developers, academic medical centers and regulatory agencies such as theFood and Drug Administration (FDA). In this session, experts from these different types of organizations will consider thebarriers and opportunities for genetics in clinical trials and clinical medicine.

Nadine Cohen, Ph.D., Head of Pharmacogenomics and Senior Research Fellow, Johnson & Johnson PharmaceuticalResearch & Development East Coast and Europe, Raritan, NJHakan Sakul, Ph.D., Senior Director and Global Head of Diagnostics, Translational and Molecular Medicine Group,Worldwide Development, Pfizer Global R&DMason W. Freeman, M.D., Chief, Lipid Metabolism Unit, Massachusetts General Hospital, Harvard Medical School,Boston, MAFelix W. Frueh, Ph.D., Associate Director, Genomics, Office of Clinical Pharmacology, CDER/FDA, Silver Spring, MD


Reception – Elements Café

5:00-6:30 Reception

Thursday, November 29, 2007



8

Morning Session - Amphitheater

TIME TOPIC SPEAKER / MODERATOR

7:30-8:30 Continental Breakfast

8:30 Molecular Biology and the Keynote Speaker: Clayton M. Christensen, D.B.A.Advent of Precision Medicine Robert and Jane Cizik Professor of Business Administration,

Harvard Business School, Cambridge, MA

Introduction by: Norman C. SelbySenior Managing Director, Perseus, L.L.C., New York, NY

9:15 Personalized Healthcare: Keynote Speaker: Wayne A. Rosenkrans, Jr., Ph.D.A Way Forward President & Chairman, Personalized Medicine Coalition,

External Relations Director – Evidence-based Medicine and Personalized Healthcare, AstraZeneca Pharmaceuticals,Wilmington, DE

Introduction by: Marcia A. KeanChief Executive Officer, Feinstein Kean Healthcare,Cambridge, MA

9:45-11:00 Session III: Who Will Pay for Moderator: Edward Abrahams, Ph.D.Personalized Medicine? Executive Director, Personalized Medicine Coalition,

Washington, DC

The costs of healthcare in the United States are growing at a pace that many believe cannot be sustained by our economy.This is exacerbated by the aging population and the needs of this group of our citizens for medical care. In this atmosphere,any new technologies or approaches to personalized medicine have to be examined carefully through the prism of costs andbenefits to society. For instance, although the cost of diagnostics is a small proportion of overall medical care, the imple-mentation of personalized medicine will result in increases in diagnostic costs. In the United States, private insurance com-panies and the Centers for Medicare & Medicaid Services (CMS) are expected to be responsible for covering the costs associ-ated with diagnostics or companion treatments. This session brings together experts from insurance companies and the leg-islative policy side to discuss the national policy issues and financial models for dealing with the shift in costs associatedwith personalized medicine.

Joanne C. Armstrong, M.D., M.P.H., Senior Medical Director for Women's Health and Clinical Lead for Genomics,Aetna, Inc., Sugarland, TXAnthony Miller, Managing Director, Lemhi Ventures, Excelsior, MN Samuel R. Nussbaum, M.D., Executive Vice President and Chief Medical Officer, Wellpoint, Inc., Indianapolis, INDora L. Hughes, M.D., M.P.H., Health Policy Advisor, Senator Barack Obama, Washington, DC


11:00 Break

Friday, November 30, 2007

Conference Program continued

9

TIME TOPIC SPEAKER / MODERATOR

11:30-12:45 Session IV: What are the Public Moderator: Gregory Downing, D.O., Ph.D.Policy and IT Issues that will Drive Program Director, Personalized Health Care, U.S. DepartmentPersonalized Medicine? of Health and Human Services, Bethesda, MD

Genetic and genomic information as it is relevant to clinical settings is accumulating at a very rapid pace. Portable electronicrecords that are capable of capturing many different types of clinical and genetic information could result in significantimprovements in the health of individuals. How to collect, store, retrieve, analyze and use this information for clinical deci-sion making is a challenge and an opportunity that has technological and public policy dimensions. The FDA is also leadingan effort to implement regulatory changes to make diagnostics safe and of proven effectiveness. Educating the public is alsoof great importance. The panelists in this session will address from the perspective of various stakeholders how policy deci-sions and technological capabilities can be harnessed to advance the excitement of personalized medicine.

Lawrence J. Lesko, Ph.D., FCP, Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Foodand Drug Administration, Silver Spring, MDSharon F. Terry, M.A., President and Chief Executive Officer, Genetic Alliance, Washington, DCJeffrey D. Miller, Vice President, WW Health and Life Sciences, WW Public Sector, Hewlett-Packard Company, Houston, TXJohn P. Glaser, Ph.D., Vice President and Chief Information Officer, Partners HealthCare, Boston, MA


12:45 Closing Raju Kucherlapati, Ph.D.Scientific Director, Harvard Medical School-Partners HealthCare Center for Genetics and Genomics, Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School,Boston, MA

1:00 Bag Lunch

Friday, November 30, 2007



10

Conference Speakers

Edward Abrahams, Ph.D.Edward Abrahams, Ph.D., Executive Director of thePersonalized Medicine Coalition, a non-profit educationaland advocacy group representing diverse members with a

interest in advancing medical progressthrough the adoption of personalizedmedicine concepts and products, bringsextensive experience in industry, acade-mia, and government to the position. Asformer Executive Director of thePennsylvania Biotechnology Association,Dr. Abrahams managed all aspects ofthe Association, including public advoca-cy, media relations, and educational pro-

grams, tripling its size and revenues in three years. He alsospearheaded the successful effort that led to theCommonwealth of Pennsylvania’s investment of $200 mil-lion to commercialize biotechnology in that state.Previously, Dr. Abrahams had been Assistant Vice Presidentfor Federal Relations at the University of Pennsylvania, andalso held a senior administrative position at BrownUniversity. Before becoming a university administrator, Dr.Abrahams worked seven years for the United StatesCongress, including as a legislative assistant to SenatorLloyd Bentsen and as an economist for the Joint EconomicCommittee under the chairmanship of Congressman LeeHamilton. In addition to articles in both popular and profes-sional journals, he is the author of The Lyrical left:Randolph Bourne, Alfred Stieglitz and the Origins ofCultural Radicalism in America.

Joanne C. Armstrong, M.D., M.P.H.Joanne Armstrong, MD, MPH is a senior medical director atAetna where she leads the areas of women’s health andgenetics. In this role, she is the clinical and strategic lead

for genomic medicine-related activitiesincluding policy development, clinicalprogram development and implementa-tion, medical cost management efforts,and other activities. Dr. Armstrong isboard-certified in obstetrics and gyne-cology and has additional training inepidemiology and public health.

Aetna is the nation’s third largesthealth benefits company, providing medical benefits fornearly 16 million individuals and pharmacy benefits for 10million individuals.

Mara G. AspinallMara Aspinall is the President of Genzyme Genetics, a lead-ing worldwide provider of testing and consultative services.Genzyme Genetics is a division of Genzyme Corporation,one of the world’s largest biotechnology firms with more

than 10,000 employees and more than $3 billion in rev-enue. From its roots 20 years ago, Genzyme Genetics hasestablished itself as one of the industry’s foremost inde-pendent diagnostics businesses, performing more than onemillion tests annually, while leading the personalized medi-cine, oncology, prenatal, postnatal, and infertility testing

markets. Genzyme Genetics has eightlaboratories across the U.S. and employsthe nation’s largest network of board-certified genetic counselors. GenzymeGenetics has achieved record growthwhile setting the quality standard withinthe diagnostics industry. Most recently,Genzyme Genetics acquired the assetsof IMPATH, Inc., one of the nation’slargest cancer testing companies, mak-

ing Genzyme Genetics one of the top commercial laborato-ries in the U.S.

Under Mara’s leadership, Genzyme Genetics has expand-ed its range and reach in the marketplace. The division hassuccessfully completed and integrated four acquisitions,expanded research and development programs, and initiat-ed new programs for community outreach and education.Most recently, Mara co-authored an article published in theHarvard Business Review titled “Realizing the Promise ofPersonalized Medicine.”

Mara previously served as President of another Genzymedivision, Genzyme Pharmaceuticals. In her four years asPresident, she restructured the business from generic drugmanufacturing to value-added custom production. She builta new international management team that created morethan 25% annual growth.

Prior to joining Genzyme, Mara was Senior Consultant atBain & Company, an international strategic consulting firm,where she specialized in developing and implementingbusiness strategies for health care product and service com-panies. Mara also served as a Director at Hale and DorrLLC.

Mara combines her professional life with active involve-ment in the community. Her two most important areas offocus are:

The fight against cancer: Mara is an active Board memberof the Dana Farber Cancer Institute, where she sits on theExecutive Committee as well as the Trustee ScienceCommittee. She has previously served as Chairman of theBoard of the American Cancer Society, Massachusetts.During her tenure at ACS, she oversaw the process of merg-ing the Massachusetts chapter into a newly formed NewEngland American Cancer Society.

Expanding educational opportunities for young children:Mara co-chairs Early Education for All, an advocacy cam-

11

paign to establish statewide standards for pre-school edu-cation. Mara is a frequent speaker to regional and nationalorganizations on creating business and legislative supportfor children’s educational programs.

Her Masters of Business Administration from HarvardBusiness School was enriched with the John P. Stevens Prizefor leadership. She has served on the board of the HBSNetwork for Women. A magna cum laude graduate of TuftsUniversity, Mara majored in International Relations.

M. Kathleen Behrens, Ph.D.Dr. Behrens presently serves as a member of the President’sCouncil of Advisors on Science and Technology (PCAST), arole in which she has served since 2001. She was a direc-tor of the Board on Science, Technology and EconomicPolicy (STEP) for the National Research Council from 1997-2005, at which time she also participated as a member ofthe Institute of Medicine Committee on New Approaches to

Early Detection and Diagnosis of BreastCancer. Kathy was a director of theNational Venture Capital Associationfrom 1993 to 2000, also serving asPresident of the NVCA from May, 1998through April, 1999, Chairman from May1999 through September, 1999 and PastChairman from October 1999 throughApril, 2000. Dr. Behrens was a Trustee of

the University of California, Davis, Foundation from 1996-2001 and also is a member of the Advisory Committee forthe J. David Gladstone Institutes. Kathy holds a Ph.D. inMicrobiology from the University of California, Davis, whereshe performed genetic research for six years.

Kathy established a career in the financial services indus-try, working with Robertson Stephens & Co. from 1983through 1996, at which time the firm was sold. During thistenure, she became a general partner and managing direc-tor. Dr. Behrens continued in her capacity as a GeneralPartner for selected venture funds for RS Investments from1996 through today, after management led a buy-out ofthat firm from Bank of America. Her professional careerincluded tenures as a public-market biotechnology securi-ties analyst, as well as venture capitalist focusing onhealthcare, technology and related investments. She wasinstrumental in the founding of several biotechnology com-panies including Protein Design Labs, Inc. and CORTherapeutics, Inc. and participated in financing a broadrange of biotechnology, health services and device compa-nies. Most recently, Kathy served as a director of Abgenix,Inc. in a role that spanned that firm’s early rounds of pri-vate financings through the company’s sale in 2006 toAmgen, Inc.

Samuel Broder, M.D.Dr. Samuel Broder joined Celera at its founding in 1998, asthe Executive Vice President for Medical Affairs and ChiefMedical Officer. Before joining the company, he had been

appointed by President Reagan to serveas Director of the National CancerInstitute in 1989, a position he held forsix years. His laboratory interests includeanti-retroviral therapy, and also, the rela-tionship between immunodeficiency dis-orders and cancer. His laboratoryfocused on the role of suppressor cells invarious immunodeficiency states and onneoplasms of immunoregulatory T cells.

His laboratory was also instrumental in developing severalof the first drugs now widely used in the therapy of AIDSand its related disorders in adults and children, especiallynucleosides such as Retrovir® (AZT), Videx®(ddI), andHIVID®(ddC). He also oversaw the development of otheragents, such as TAXOL®. While serving as NCI Director, hehelped launch a number of large-scale clinical trials relatedto the prevention, diagnosis, and treatment of cancer andinaugurated the SPORE Program. He is the author or co-author of over 330 scientific publications. He has receivednumerous scientific awards related to his research in cancerand AIDS. His current interests relate to applying knowledgeof the human genome, DNA diagnostics, and proteomics tothe development of new strategies to treat cancer.

Clayton M. Christensen, D.B.A.Clayton M. Christensen is the Robert and Jane CizikProfessor of Business Administration at the HarvardBusiness School, with a joint appointment in the Technology& Operations Management and General Management fac-ulty groups. His research and teaching interests center onthe management issues related to the development andcommercialization of technological and business modelinnovation. Specific areas of focus include developing orga-nizational capabilities and finding new markets for newtechnologies.

Professor Christensen holds a B.A. with highest honors ineconomics from Brigham Young University (1975), and anM.Phil. in applied econometrics and the economics of less-developed countries from Oxford University (1977), wherehe studied as a Rhodes Scholar. He received an MBA withHigh Distinction from the Harvard Business School in 1979,graduating as a George F. Baker Scholar. He was awardedhis DBA from the Harvard Business School in 1992.Prior to joining the HBS faculty, Professor Christensenserved as chairman and president of Ceramics ProcessSystems Corporation (CPS), a firm he co-founded with sev-eral MIT professors in 1984. CPS is a leading developer ofproducts and manufacturing processes using high-technolo-

continued



12

Conference Speakers continued

gy metals and ceramics such as silicon nitride and siliconcarbide. From 1979 to 1984 he worked as a consultant andproject manager with the Boston Consulting Group (BCG),where he was instrumental in founding the firm's manufac-turing strategy consulting practice. In 1982 ProfessorChristensen was named a White House Fellow, and servedthrough 1983 (on a leave of absence from BCG) as assis-tant to U.S. Transportation Secretaries Drew Lewis andElizabeth Dole.

Professor Christensen became a faculty member at theHarvard Business School in 1992. He taught courses inTechnology and Operations Management, GeneralManagement, and Operations Strategy. He then developeda course called Managing Innovation. Professor Christensencurrently teaches an elective course he designed calledBuilding a Sustainably Successful Enterprise, which teachesmanagers how to build and manage an enduring, success-ful company or transform an existing organization.

Professor Christensen is the author of the bestsellingbooks The Innovator’s Dilemma (1997), which received theGlobal Business Book Award for the best business bookpublished in 1997, The Innovator's Solution (2003), andSeeing What's Next (2004). In addition, he edited two case-books on Innovation: Innovation and the General Manager(1999) and Strategic Management of Technology andInnovation, 4th edition (2004).

Professor Christensen's writings have been featured in avariety of publications, and have won a number of awards,such as the Best Dissertation Award from The Institute ofManagement Sciences for his doctoral thesis on technologydevelopment in the disk drive industry; the Production andOperations Management Society's 1991 William AbernathyAward, presented to the author of the best paper in themanagement of technology; the Newcomen Society’s awardfor the best paper in business history in 1993; and the 1995and 2001 McKinsey Awards for articles published in theHarvard Business Review.

Professor Christensen was born in Salt Lake City, Utah.He worked as a missionary for the Church of Jesus Christ ofLatter-Day Saints in the Republic of Korea from 1971 to1973 and speaks fluent Korean. He continues to serve in hischurch in a variety of ways and is extensively involved inother activities in the community. He served from 1986 to1994 as a member of the Program Review Board andStrategic Planning Committee of the Brigham and Women'sHospital in Boston, and was a member and chairman of theboard of directors of the Massachusetts Affiliate of theAmerican Diabetes Association between 1984 and 1996.Professor Christensen was also a founding board memberof the Combined Health Appeal of NortheasternMassachusetts. He was an elected member of the TownMeeting (council) in Belmont Massachusetts for eight years;

served as vice-chairman of the town's personnel board; andas chairman of its long-range financial planning task force.He has served the Boy Scouts of America for 25 years as ascoutmaster, cubmaster, den leader and troop and packcommittee chairman. He and his wife Christine live inBelmont, MA. They are the parents of five children.

Nadine Cohen, Ph.D.Nadine Cohen was trained as a pharmacist in France andreceived her Ph.D. in Immunogenetics in 1986 from theHebrew University in Jerusalem. She was a post-doctoratefellow at Stanford University until 1989, and after heading

the genetic screening laboratory at theFoundation Jean Dausset-HumanPolymorphism Study Center in Paris, shewas an Assistant Professor from 1995-2001 at the Technion Bruce RappaportFaculty of Medicine in Haifa (Israel). Shejoined the Jansen Research Foundationin August 1999 to establish aPharmacogenomics program. She is cur-rently Head of the Pharmacogenomics

Team at the Johnson and Johnson Pharmaceutical Researchand Development (Raritan, NJ, USA). She has publishedmore than 60 scientific papers in the area of immunogenet-ics and human molecular genetics. Nadine Cohen is alsothe current elected chair of the industry PharmacogeneticsWorking Group, and represents Johnson and Johnson onvarious external organizations engaged inPharmacogenomics and Personalized Medicine.

Gregory J. Downing, D.O., Ph.DDr. Downing is Director of the Office of Technology andIndustrial Relations (OTIR) in the Office of the Director atthe National Cancer Institute (NCI), National Institutes ofHealth. In this role, he facilitates the collaboration amongFederal, academic, and private biomedical research sectorsto support technology development that will yield innova-tive diagnostic, detection, and targeted treatment strategiesfor cancer. Through the OTIR, he supervises the administra-tion of grants and contracts for programs in nanotechnolo-gy, biosensors, therapeutic delivery systems, and new tech-nology platforms and imaging systems. He currently serveson several committees, including the NCI-FDA InteragencyOncology Task Force and the Biomedical InformationScience and Technology Consortium.Dr. Downing began his career at the NIH in 1994 as a fel-low at the National Institute for Child Health and HumanDevelopment, and subsequently served in the Office ofScience Policy and Planning as a health science policy ana-lyst and deputy director. Today, he continues to lead theimplementation of training and programs that support the

13

research policy goals of the NIH.Dr. Downing earned his medical degree from Michigan

State University and his Ph.D. in pharmacology from theUniversity of Kansas. He completed his residency in pedi-atrics and fellowship in neonatology before joining the fac-ulty of the University of Missouri-Kansas City in theDepartment of Neonatology at The Children’s MercyHospital.

Dr. Downing is certified by the American Board ofPediatrics in pediatrics and neonatology— perinatal medi-cine. He sits on the editorial board of the Journal ofMaternal-Fetal Investigation and is Associate Editor ofDisease Biomarkers. He has published numerous articlesand research in the fields of pharmacology and medicineand has contributed to three books.

Deborah Dunsire, M.D., President and CEO Dr. Dunsire joined Millennium in July, 2005 with nearly 20years of experience in commercial, operational, clinical andscientific aspects of a world-leading pharmaceutical busi-ness.

Her vision for Millennium is to establish a vibrant, grow-ing biotechnology company, which dis-covers and develops new medicines thatchange standards of care in cancer andinflammation.

Previously, Dr. Dunsire led the NovartisU.S. Oncology business and played acritical role in the broad developmentand launch of successful products suchas Zometa®, Femara® and Gleevec®.Notably, Dr. Dunsire managed 12 prod-

uct launches and built the business from approximately $50million to $2.1 billion in revenues over 10 years. Dr. Dunsirealso was responsible in the U.S. for managing the mergerand significant growth of the combined SandozPharmaceuticals and Ciba-Geigy oncology businesses.

Earlier in her career, she was a clinical researcher respon-sible for the implementation of global Phase II and Phase IIIstudies across multiple therapeutic areas, includingimmunology, endocrinology, neurology, dermatology, oncol-ogy and transplantation.

Dr. Dunsire graduated from medical school at theUniversity of Witwatersand in Johannesburg, South Africa.In 2006, she was also awarded a Doctor of Science, HonorisCausa, from Worcester Polytechnic Institute. Currently, Dr.Dunsire is a board member of the Pharmaceutical Researchand Manufacturers of America (PhRMA), BiotechnologyIndustry Organization (BIO), Allergan, Inc. and the G&PFoundation for Cancer Research. In 2001, she was therecipient of the American Cancer Society Excalibur award,the 2000 recipient of the Health Care Business Women’s

Association Rising Star award and also the Creative Spiritaward from the Creative Center for Women with Cancer.

Mason Freeman, M.D.Mason Freeman, MD is Chief of the Lipid Metabolism Unitat Massachusetts General Hospital, Harvard MedicalSchool. Trained in internal medicine and endocrinology, Dr.

Freeman has spent the past twenty yearsstudying the trafficking of cholesterolinto and out of macrophages. He found-ed and still directs the Lipid Clinic atMGH and is an internationally recog-nized expert in the treatment of lipiddisorders. In 2005, Dr. Freeman took asabbatical from Harvard to work as Vice-President and Global Head ofTranslational Medicine for

Cardiovascular, Diabetes, and Metabolic Diseases at theNovartis Institutes of Biomedical Research in Cambridge,MA. In this role, he and his translational medicine teamwere responsible for designing the early development pro-grams for drugs affecting hypertension, diabetes, obesity,atherosclerosis and lipid disorders. On returning to MGH in2007, he assumed the dual roles of Director of theGenetics Enters Medicine trials in Partners and Director ofTranslational Medicine at MGH. Dr. Freeman received hisA.B from Harvard College, M.D. from the University ofCalifornia, San Francisco, and did post-doctoral training incell biology and lipid metabolism at MIT.

Felix W Frueh, Ph.D.Dr. Frueh holds the position of Associate Director forGenomics in the Office of Clinical Pharmacology (OCP) inthe Center for Drug Evaluation and Research (CDER) at the

FDA and also chairs the FDA-wideInterdisciplinary PharmacogenomicsReview Group (IPRG). Prior to hisappointment at the FDA, Dr. Frueh wasManaging Partner at StepoutsideConsulting, LLC, and served as a SpecialGovernment Employee to the FDA andas a consultant to the CDC’s NHANESproject. He held the position ofResearch Director for Pharmacogenetics

at Transgenomic, Inc., managing the expansion of the busi-ness into new program areas for the diagnosis of geneticdisorders. Prior, Dr. Frueh was the Assistant Director forBiology at Protogene Laboratories, Inc., responsible forapplication development based on novel, in situ synthe-sized DNA microarray technology. He held an appointmentas Assistant Professor at Georgetown University,Washington, DC in the Departments of Pharmacology and

continued



14


Medicine and was a postdoctoral fellow at StanfordUniversity and at the Biocenter of the University of Basel,Switzerland. Felix is a native of Basel and lives in Marylandwith his wife and two sons.

John P. Glaser, Ph.D.John Glaser, PhD, is Vice-President and Chief InformationOfficer, Partners HealthCare System, Inc. Previously, he wasVice-President, Information Systems at Brigham and

Women’s Hospital. Prior to Brigham andWomen’s Hospital, Dr. Glaser managedthe Healthcare Information Systems con-sulting practice at Arthur D. Little.

Dr. Glaser was the founding Chairmanof College of Healthcare InformationManagement Executives (CHIME) and ispast President of the HealthcareInformation and Management SystemsSociety (HIMSS). He has been a member

of the Board of the American Medical InformaticsAssociation.

Dr. Glaser is currently the Chairman of the eHealthInitiative Board and the Senior Advisor for National HITAdoption for CHIME. He is a Senior Advisor to the DeloitteCenter for Health Solutions.

He is a fellow of HIMSS, CHIME and the AmericanCollege of Medical Informatics. He has been awarded theJohn Gall award for healthcare CIO of the year. CHIME hasestablished a scholarship in Dr. Glaser’s name. He was arecipient of CIO Magazine’s 20/20 Vision Award. PartnersHealthCare has received several industry awards for itseffective and innovative use of information technology.

Dr. Glaser has published over one hundred articles andfour books on the strategic application of information tech-nology in healthcare.

He holds a Ph.D. in Healthcare Information Systems fromthe University of Minnesota.

Richard G. Hamermesh, D.B.A.Richard Hamermesh is the MBA Class of 1961 Professor ofManagement Practice at the Harvard Business Schoolwhere he teaches in the MBA Program and is the FacultyChair of the HBS Healthcare Initiative. Richard created andteaches the second-year MBA elective, Entrepreneurship

and Venture Capital in Healthcare.Previously, he was the Course Head forthe required first year course entitledThe Entrepreneurial Manager.

From 1987 to 2001, Richard was a co-founder and a Managing Partner of TheCenter for Executive Development, anexecutive education and development

consulting firm. Prior to this, from 1976 to 1987, he was amember of the faculty of the Harvard Business School.Richard is also an active investor and entrepreneur, havingparticipated as a principal, director, and investor in thefounding and early stages of over 20 organizations. Thesehave included start-ups, leveraged buy-outs, industry roll-ups, and non-profit foundations. He was the founding presi-dent of the Newton (MA) Schools Foundation and servedon the editorial board of the Harvard Business Review. He iscurrently on the Boards of one public and two private cor-porations, as well as two non-profit Boards. From 1991 to1996, he was the founding Chairman of Synthes Spine, Inc.

Richard is the author or co-author of five books, includ-ing New Business Ventures and the Entrepreneur. His best-known book, Fad-Free Management, was published in1996. He has published numerous articles and more than100 case studies. His most recent article, “Realizing thePotential of Personalized Medicine,” will appear in theHarvard Business Review (October 2007). Richard receivedhis AB from the University of California, and his MBA andDBA from HBS. He is married, has two children, and hishobbies include tennis, skiing, and yoga.

Dora L. Hughes, M.D., M.P.H.Dr. Dora Hughes advises Senator Barack Obama on a broadrange of health issues and helps to develop his nationalpolicy and legislative agenda. She previously served asDeputy Director for Health for Senator Edward M. Kennedyon the Committee on Health, Education, Labor andPensions in the United States Senate. Prior to working onCapitol Hill, Dr. Hughes served as Senior Program Officer atThe Commonwealth Fund, a national health foundation inNew York City. She completed medical school at VanderbiltUniversity, residency at Brigham & Women's Hospital andpublic health school at Harvard University. Dr. Hughes isboard-certified in internal medicine.June 2007.

Marcia A. KeanMarcia Kean was appointed Chief Executive Officer ofFeinstein Kean Healthcare (FKH) in December 2002. In thatrole, she leads a team of 60+ professionals located inCambridge, Massachusetts; San Francisco, California; Iselin,New Jersey: and Washington, DC. Mrs. Kean has a 25+

year track record in the life sciences,counseling CEOs and senior leadershipin the use of communications to meetbusiness and organizational objectives.

In 2003, Mrs. Kean founded the firstMolecular Medicine communicationspractice in the country, to help clientsmanage the opportunities and issues

15

inherent in the molecular-based transformation of healthcare. She has subsequently become a thought leader in thefield, through her publications and speaking engagementsin the United States and internationally. Mrs. Kean currentlyserves as an advisor to the Board of Directors of thePersonalized Medicine Coalition, and was awarded thatorganization’s first Distinguished Service Award in 2006.She is also a member of the Genetics Advisory Council ofthe Harvard-Partners Center for Genetics and Genomics.She served in 2007 as a member of a PersonalizedMedicine Expert Panel convened by the Office of theAssistant Secretary for Planning and Evaluation (ASPE) ofthe US Department of Health and Human Services, toexplore factors related to the integration of personalizedmedicine into clinical and public health practice. She hasalso been invited to serve on the Institute of MedicineRoundtable on Evidence-Based Medicine CommunicationCollaborative.

Mrs. Kean holds an MBA in Finance from New YorkUniversity, and a BA from the University of California atBerkeley.

Michael O. LeavittMichael O. Leavitt was sworn in as the 20th Secretary ofthe U.S. Department of Health and Human Services onJanuary 26, 2005. As secretary, he leads the Nation’s effortsto protect the health of all Americans and provide essential

human services to those in need. Hemanages one of the largest civiliandepartments in the federal government,with a budget that accounts for almostone out of every four federal dollars andmore than 67,000 employees.During his first year, he led efforts tosuccessfully enroll tens of millions ofseniors and disabled persons in the newMedicare prescription drug benefit;

mobilized the nation’s pandemic preparedness; acceleratedthe development of health information standards and over-saw the medical response to Hurricane Katrina. He alsopresided over changes in Medicaid statutes to give statesflexibility to provide targeted insurance coverage to morepeople, and reauthorization by Congress, after ten exten-sions, of the Temporary Assistance to Needy Families.

He is intensively focused on making health care moretransparent in quality and price, and reducing the time andexpense of bringing safe and effective drugs to market.Prior to his current service, Leavitt served as head of theU.S. Environmental Protection Agency and three-termGovernor of Utah.

During his eleven years of service, Utah was recognizedsix times as one of America’s best managed states. He was

chosen by his peers as Chairman of the National GovernorsAssociation, Western Governors Association and RepublicanGovernors.

Prior to his public service, he served as president andchief executive officer of a regional insurance firm, estab-lishing it as one of the top insurance brokers in America. Heis married to Jacalyn S. Leavitt; they are the parents of fivechildren.

John C. Lechleiter, Ph.D.John C. Lechleiter, Ph.D., was named president and chiefoperating officer in October 2005. He previously served asexecutive vice president, pharmaceutical operations since

January 2004. He had been executivevice president for pharmaceutical prod-ucts and corporate development since2001. Lechleiter is a member of the com-pany’s policy and strategy committee,and also chairs the company’s opera-tions committee.

Lechleiter received a bachelor of sci-ence degree summa cum laude in chem-istry from Xavier University (Cincinnati,

Ohio) in 1975. He studied organic chemistry as a NationalScience Foundation Fellow at Harvard University, where hereceived his master’s and doctorate degrees in 1980. In2006, Lechleiter received an honorary doctorate of businessadministration from Marian College of Indianapolis.Joining Lilly in 1979 as a senior organic chemist in processresearch and development, Lechleiter became head of thatdepartment in 1982. In 1983, he began serving as directorof pharmaceutical product development for the LillyResearch Center Limited, in Windlesham, England.He returned to the United States in 1986 as manager ofresearch and development projects for Europe. In 1988, hebecame director of development projects management andsubsequently assumed additional responsibility for pharma-ceutical regulatory affairs: chemistry, manufacturing, andcontrol in 1989. In 1991, he was named executive directorof pharmaceutical product development and became vicepresident in 1993. He was appointed vice president of regu-latory affairs in 1994. In 1996, he was named vice presidentof Lilly Research Laboratories, a division of Eli Lilly andCompany, responsible for development and regulatoryaffairs. Lechleiter became senior vice president, pharmaceu-tical products in 1998.

Lechleiter is a member of the American Chemical Society.In 2004, he was appointed to the Visiting Committee ofHarvard Business School and to the Health Policy andManagement Council of the Harvard School of PublicHealth. He also serves as a member of the Board ofTrustees of Xavier University in Cincinnati. In addition, he

continued



16


serves as a distinguished advisor of The Children’s Museumof Indianapolis, a member of the Dean’s Advisory Council atthe Indiana University School of Medicine, a member of theBoard of Directors and Executive Committee of FairbanksInstitute, and a member of the United Way of CentralIndiana Board of Directors.

Lawrence J. Lesko, Ph.D., FCPLawrence J. Lesko, Ph.D., FCP has been the Director of theOffice of Clinical Pharmacology in the Center for DrugEvaluation and Research at the Food and DrugAdministration since 1995. The main focus of Dr. Lesko’sOffice is the translational analysis of dose-response and PK-PD data for the purposes of optimizing dosing and the ben-efit/risk ratio of FDA-approved drugs, the use of PK and bio-markers to assist in dosing adjustments for drug-drug inter-actions, special populations (e.g., renal patients) and otherpatient subsets defined by pharmacogenomics, individual-ization of drug therapy using plasma drug levels, and theapplication of quantitative methods such as disease stateprogression models and simulations to design clinical trials.Outside FDA, Dr. Lesko has served as President of theAmerican College of Clinical Pharmacology (2004-2006).Prior to joining FDA, Dr. Lesko was a faculty member in aca-demia for over 15 years, most recently at the University ofMaryland. He has directed the clinical pharmacology labo-ratory at the University of Massachusetts Medical Center,and was Vice-President of PharmaKinetics Laboratories, aBaltimore-based contract research organization. He hasbeen appointed as an Adjunct Professor at the University ofFlorida and at the University of Southern California in theColleges of Pharmacy where he lectures and interacts withgraduate students. Dr. Lesko is an American Association ofPharmaceutical Scientist (AAPS) Fellow and is BoardCertified in Clinical Pharmacology by the American Board ofClinical Pharmacology. He received the Rawls-PalmerProgress in Medicine Award from the American Society ofClinical Pharmacology and Therapeutics in March 2007, theUniversity of North Carolina Institute of PersonalizedMedicine Clinical Services Award in May 2007 and theNathaniel T. Kwit Memorial Distinguished Service Awardfrom the American College of Clinical Pharmacology inSeptember 2007. He is a member of the editorial board ofseveral prestigious journals including the Journal of ClinicalPharmacology. He has over 145 publications in peer-reviewed journals and is a frequent invited speaker nation-ally and internationally. His hobbies are motorcycle riding,scuba diving and underwater photography. He is aDivemaster certified by the Professional Association ofDiving Instructors.

Mark J. LevinMark is an industry visionary with more than 25 years ofexperience building and operating leading biotech compa-nies. After ten years at Lilly and Genentech, Mark was co-founder of Mayfield life sciences effort where he wasfounding CEO of Tularik, Cell Genesys/Abgenix, Focal, Stem Cells and Millennium Pharmaceuticals.Mark was at Millennium as CEO for 12 years and builtwhat is recognized as the highest valued life sciences com-pany since 1990.

Anthony MillerTony Miller co-founded Lemhi Ventures in 2006 to build thecapital base and value added approach of forming andhelping companies continue to advance the marketization

of the healthcare industry.Additionally, Mr. Miller is part of the

leadership team at Carol Corporation, aLemhi Ventures Portfolio company. Mr.Miller serves on the Boards ofVisionShare, and Carol Corporation.Prior to founding Lemhi Ventures, Mr.Miller was a co-founder and CEO ofDefinity Health, a national market leaderin consumer-driven health benefit pro-

grams, which was sold to UnitedHealth Group in 2004.Mr. Miller regularly serves as an industry expert in arti-

cles and other news coverage and is a frequent speaker onthe topics of consumer-driven healthcare and health policy.Prior to founding Definity Health, Mr. Miller was a consult-ant at Deloitte Consulting where he focused on strategicbusiness development in the managed care industry, includ-ing mergers and acquisition, market development and per-formance turnarounds. Mr. Miller holds an M.B.A. fromCornell University’s Johnson Graduate School ofManagement and an M.S. in Kinesiology from theUniversity of Illinois at Champaign-Urbana.

Jeffrey D. MillerAs Vice President, Worldwide Health and Life Sciences(HLS), Jeff Miller is responsible for market strategy, businessplanning, service offerings, and solutions development forthe healthcare provider, health insurer,

pharmaceutical/biotech, and life sci-ences research market segments. Heoversees the marketing and salesactivities for this industry sector, drivingoverall effectiveness and impact on aglobal scale. In addition, Miller hasresponsibility for strategic oversight ofHP’s global sales and services efforts inthe Public Sector. For several years,

17

Miller has focused his activities on enabling the transforma-tion of the HLS industry as it has evolved from departmen-tal technology solutions into an ecosystem with an inte-grated set of solutions that allow participants across thevalue chain to digitize content, analyze data, and managetheir information collaboratively and effectively, and wherethe quality of patient care is critical to sustainable competi-tive advantage. During his tenure, industry analysts reportthat HP HLS revenues have grown to more than $5 billionannually. Miller has more than twenty years experience instrategic planning, product development, and operationalprocess improvement in the health care, manufacturing,public sector, and technology industries. Prior to joining HP,he led the development and delivery of management con-sulting services at The Advisory Board Company andDeloitte Consulting. He has worked with a diverse set ofHealth industry organizations on the identification anddevelopment of transformational strategies and the imple-mentation of technology-enabled business processes.Previously, he managed a variety of business strategy, prod-uct planning, and development operations organizations atIBM.

Miller is based in Research Triangle Park, North Carolina.He holds a master’s of Business Administration from theFuqua School of Business at Duke University in Durham,North Carolina, and a bachelor’s in Economics fromNorthwestern University in Chicago. © 2007 Hewlett-Packard Development Company, L.P. 04/2007

Thomas J. MillerMiller holds an impressive professional track record withinSiemens and other multinational corporations. During hisinitial 15-year tenure with Siemens, Miller headed up Med’sMagnetic Resonance (MR) product division, and the U.S.sales and service organization. Afterwards Miller was vicepresident, Business Development, for Siemens MedicalSolutions in Erlangen, Germany. Most recently, he led theSiemens Medical Solutions Health Services Corporation(HS).

Miller will tell you that there isn’t a lack of information inthe healthcare industry, but rather, it’s perfecting the man-agement of that information that will help healthcareorganizations become more efficient and positively impactpatient outcomes. His mission is to achieve the goals ofassuring patient safety, increasing operational efficiencyand improving clinical outcomes for all of Siemens’ IT cus-tomers. Doing this means moving information through thehealthcare continuum in an effective and meaningful way,analyzing and using it to continuously improve the process-es involved in today’s standards of care, resulting in trueworkflow optimization, expanding beyond the automationof manual processes.

In addition to his leadership positions at Siemens, Milleralso was president and CEO of Carl Zeiss, Inc., the Americansubsidiary of the optical company, and simultaneously thegeneral manager of their worldwide medical division,responsible for surgical microscopes and ophthalmologyproducts. Tom also served as president and CEO of AnalogicCorporation, a manufacturer of components and subsys-tems for the healthcare and security industry. He also co-founded a company, LightLab Imaging, to commercialize anew diagnostic-imaging method called optical coherencetomography (OCT), which enables the acquisition and dis-play of real-time ultra high-resolution, cross-sectionalimages with light. During the summer of 2002, followingsuccessful initial clinical trials for vulnerable plaque imag-ing in coronary arteries, he sold the operation to a Japanesecompany.

Whether he is racing motorcycles, bicycling, reading aclassic or listening to music, the one thing that remainsconstant is Miller’s passion for life. This exuberance is alsotrue in is his commitment to his work. As Miller sees it, thepotential for healthcare IT is boundless and the exponen-tially increasing pace of technological advances offer greatpossibilities to those who can leverage it.

Miller holds a B.S. in nuclear engineering with a minor inEnglish literature from the University of Massachusetts anda master’s degree from Harvard Medical School/MIT’s jointprogram in medical physics.

James J. Mongan, M.D.Dr. Mongan is president and chief executive officer ofPartners HealthCare in Boston, an integrated health systemfounded in 1994 by Brigham and Women’s Hospital andMassachusetts General Hospital.

In addition to its two academic med-ical centers, the Partners system alsoincludes community hospitals, specialtyhospitals, community health centers, aphysician network, home health andlong-term care services, and otherhealth-related entities.

Partners is one of the nation’s leadingbiomedical research organizations anda principal teaching affiliate of Harvard

Medical School.A professor of health care policy and a professor of social

medicine at Harvard Medical School, Dr. Mongan alsoserves on the board of the Commonwealth Fund and chairsits Commission on a High Performance Health System.

Prior to being appointed president and CEO of Partners,Dr. Mongan was president of Massachusetts GeneralHospital, the largest and oldest teaching affiliate of HarvardMedical School. He also served for 15 years as executive

continued



18


director of the Truman Medical Center in Kansas City, alarge public hospital, where he also served as dean of theUniversity of Missouri-Kansas City School of Medicine.

Dr. Mongan spent 11 years in Washington as staff to theSenate Finance Committee, working on Medicare andMedicaid legislation. He later served in the Carter adminis-tration as deputy assistant secretary for health and then atthe White House as associate director of the domestic poli-cy staff.

Dr. Mongan is a member of the Institute of Medicine ofthe National Academy of Sciences. He has served on theboards of the American Hospital Association and the KaiserFamily Foundation, and was a member of both theProspective Payment Assessment Commission establishedby Congress and the Institute of Medicine’s Commission onthe Consequences of Uninsurance.

A native of San Francisco, Dr. Mongan received his under-graduate education at the University of California, Berkeley,and Stanford University, and his medical degree fromStanford University Medical School. He completed hisinternship at the Kaiser Foundation Hospital in SanFrancisco and served for two years in the U.S. Public HealthService.

Garry Neil, M.D.Garry Neil, M.D. is Corporate Vice President, CorporateOffice of Science & Technology (COSAT), Johnson &Johnson. In this role, Garry leads a team that catalyzes sus-

tained cross-sector growth for Johnson& Johnson by identifying and launchingemerging technologies that underpin thecreation of future businesses.

He has broad experience in the sci-ence, medicine and pharmaceuticalresearch and development. He has helda number of senior positions within J&J,most recently Group President, Johnsonand Johnson Pharmaceutical Research

and Development. Under his leadership a number ofimportant new medicines for the treatment of cancer, ane-mia, infections, central nervous system and psychiatric dis-orders, pain, and genitourinary and gastrointestinal dis-eases, gained initial or new and/or expanded indicationapprovals.

Garry joined J&J in 2002. He previously held senior-levelpositions with Astra Merck Inc., Astra Pharmaceuticals,Astra Zeneca and Merck KGaA. He has also held a numberof academic posts at a number of academic institutesincluding the Ludwig Institute for Cancer Research, theUniversity of Toronto, the University of Iowa College ofMedicine and the University of Pennsylvania (adjunct). Hehas written more than 50 articles and book chapters. He is

a Fellow of the American College of Physicians, a Fellow ofthe American College of Gastroenterology, a member of theAmerican Association of Immunologists, and the Society forClinical Trials. He is a member of the Board of the J&JDevelopment Corporation and is J&J’s representative to,and Vice Chairman, of the Pharmaceutical Research andManufacturers Association (PhRMA) Science and RegulatoryCommittee, Vice Chairman and Treasurer of the PhRMAFoundation Board, a member of the Board of Trustees forthe University of Medicine and Dentistry of New Jersey, amember of the Executive Committee of the BiomarkersConsortium, and a member of the Board of Trustees of theNewark Boys Chorus School.

Samuel R. Nussbaum, M.D.Dr. Samuel Nussbaum is executive vice president and chiefmedical officer for WellPoint, Inc. He oversees corporatemedical policy, clinical pharmacy programs, health improve-

ment and quality resources, programsfor clinical excellence, disease and caremanagement, and clinical informatics tooptimize care for members. Dr.Nussbaum also has responsibility for theHealth Management Corporation (HMC)and HealthCore subsidiaries. WhenAnthem, Inc. merged with WellPointHealth Networks Inc. in November 2004and was subsequently renamed

WellPoint, Inc., Dr. Nussbaum was serving as executive vicepresident and chief medical officer of Anthem. He joinedAnthem in January 2001.

His principal responsibilities continue to include: servingas chief spokesperson on medical issues, guiding the corpo-rate vision regarding quality of care and its measurements,leading efforts to assess cost of care performance anddeveloping a strategy to foster further collaboration withphysicians and hospitals to strengthen and improve patientcare.Dr. Nussbaum has served as president of the DiseaseManagement Association of America, Chairman of theNational Committee for Quality Health Care, as Chair ofAmerica’s Health Insurance Plan’s (AHIP) Chief MedicalOfficer Leadership Council and as a member of the AHIPBoard. He received the 2004 Physician Executive Award ofExcellence from the American College of PhysicianExecutives and Modern Physician magazine. Dr. Nussbaumis a member of numerous professional organizations andhas spoken at national and regional conferences pertainingto his medical research as well as on health-care delivery.Dr. Nussbaum is professor of clinical medicine atWashington University School of Medicine and serves asadjunct professor at the Olin School of Business,

19

Washington University.Dr. Nussbaum served as executive vice president, Medical

Affairs and System Integration, of the BJC Health System-one of the largest academic and community integratedhealth and hospital systems in the United States, where healso served as CEO of its health plan and president of itsmedical group.

Dr. Nussbaum earned his medical degree from MountSinai School of Medicine. He trained in internal medicine atStanford and Harvard and in endocrinology and metabolismat Harvard and Massachusetts General Hospital, where hedirected the Endocrine Clinical Group and theMusculoskeletal Pathophysiology course at Harvard MedicalSchool. His clinical and basic research has led to new thera-pies to treat skeletal disorders and new technologies tomeasure hormones in blood. Nussbaum is board-certified ininternal medicine and specialty certified in endocrinologyand metabolism.

Wayne A. Rosenkrans, Jr., Ph.D.Wayne is Director of External Relations for the PersonalizedHealthcare Team at AstraZeneca and for Evidence-basedMedicine (EBM) as part of External Medical Relations

where he has responsibility for long-range external relations strategy andpolicy development. He is Chairman,President and a member of the board ofdirectors of the Personalized MedicineCoalition, a Washington DC basedorganization working with governmentand other agencies on evolving health-care policy for Personalized Healthcare.He also is involved in a number of work-

streams at the Institute of Medicine (IOM), and representsAZ on several strategy and advisory boards at differentorganizations including the Health Industry Forum, NationalPharmaceutical Council, C-Path Institute, MIT, GeorgetownUniversity, IBM, and the Personalized Healthcare Initiativein the Secretary’s office at Health and Human Services. Hehas presented at numerous forums on aspects of personal-ized healthcare, evidence-based medicine, new develop-ment paradigms, and strategy development. He holds anS.B. in Biology from MIT, a Ph.D. in Cell and MolecularBiology from Boston Univ., and received post-doctoral train-ing in Cancer and Radiation Biology at the Univ. ofRochester. Wayne is based in Wilmington, is married withtwo college-age children, and enjoys teaching martial arts(Tang Soo Do), restoring antique/classic Fords, and aviationhistory.

Hakan Sakul, PhDSenior Director and Global Head of DiagnosticsTranslational and Molecular Medicine Group, Clinical R&DPfizer Global R&D, New London Laboratories, Connecticut,USA

Since May 2007 Hakan has been a Senior Director in theTranslational and Molecular MedicineGroup where he is the Global Head ofDiagnostics, leading Pfizer’s Diagnosticseffort across all therapeutic areas.Hakan joined Parke-Davis in December1998 as Director of Human Genetics,Statistical Genetics andPharmacogenetics programs. Due tosite closure shortly after Pfizer’s mergerwith Warner-Lambert, he moved to

Ardais Corporation in Lexington, MA as Vice President ofStatistical Genomics, after which he returned to Pfizer inNovember 2001 as Director and Site Head for ClinicalPharmacogenomics in Groton/New London Laboratories.Hakan was promoted to Senior Director in mid-2005 andwas responsible for programs in CNS and InfectiousDiseases prior to assuming his current role.

Hakan is a native of Turkey where he completed his BSand MS degrees. He then completed his PhD degree inQuantitative Genetics at the University of Minnesota as aRotary Foundation Scholar. He completed a postdoctoralprogram at the University of California, Davis in quantita-tive genetics, animal genetics and international agriculturebefore moving into the biotech industry in human geneticsand pharmacogenomics in 1995. Hakan has authored over30 scientific refereed articles, several book chapters, andserved as invited speaker on many panels and scientificmeetings. He represents Pfizer on the Clinical Science andTechnology Committee of Personalized Medicine Coalition,and Pharmacogenetics Working Group. Hakan is keenlyinterested in applications of diagnostics, pharmacoge-nomics and other –omics to the pharmaceutical pipeline asa business enabler, and their applications in improving andindividualizing patient care.

Peer M. SchatzPeer M. Schatz is QIAGEN’s Chief Executive Officer andChairman of the Executive Committee. He joined QIAGEN in

1993 as Chief Financial Officer. Mr.Schatz was previously a partner in a pri-vate management buyout group inSwitzerland and worked in finance andsystems positions in Sandoz, Ltd. andComputerland AG as well as in finance,operations, management and sales posi-tions in various start-up companies in

continued



20

the computer and software trading industry in Europe andthe United States. Mr. Schatz graduated from the Universityof St. Gall, Switzerland, with a Master’s degree in Financein 1989 and obtained an M.B.A. in Finance from theUniversity of Chicago Graduate School of Business in 1991.Mr. Schatz is a member of the German CorporateGovernance Commission.

Christine Seidman, M.D.Christine (Kricket) Seidman is a Professor in theDepartments of Medicine and Genetics at Harvard MedicalSchool and Brigham and Women’s Hospital. In 2005 she

was named the Thomas W. SmithProfessor of Medicine. She is also anInvestigator of the Howard HughesMedical Institute. She was an under-graduate at Harvard College andreceived a M.D. from GeorgeWashington University School ofMedicine in 1978. Dr. Seidman servedas an intern and resident in InternalMedicine at John Hopkins Hospital and

received subspecialty training in cardiology at theMassachusetts General Hospital. She joined the staff atBrigham and Women’s Hospital in 1987 and is currently theDirector of the Cardiovascular Genetics Center.

Honors include: Marion Hypertension Research Award(1984); American Heart Association Clinician-ScientistAward (1986); Bristol-Myers Squibb UnrestrictedCardiovascular Research Grant Award (1990); AmericanHeart Association Established Investigatorship Award(1992); Robert J. and Claire Pasarow Foundation Award inCardiovascular Research (1992); American HeartAssociation, Edgar Haber Cardiovascular Award (1997);American Heart Association, Helen B. Taussig MemorialLecturer (1997); Member, Johns Hopkins University Societyof Scholars (1998); Member, American Academy of Arts andSciences (1999); Member, Institutes of Medicine (1999);American Heart Association, Basic Research Prize (1999);Gill Heart Institute Award for Cardiovascular Research(2000); American College of Cardiology, Louis F. BishopLecture (2000); Gill Heart Institute Award for CardiovascularResearch (2001); 12th Annual Bristol-Myers Squibb Awardfor Distinguished Achievement in Cardiovascular Research(joint recipient with Jonathan Seidman, PhD) (2002); Fellow,International Society Heart Research (2002); DistinguishedScientist, American Heart Association (2003); CannonAward, American Physiologic Society (2004); Member,Association of University Cardiologists (2005);Distinguished Alumni Achievement Award, The GeorgeWashington University (2005); Member, National Academyof Sciences (2005); Lefoulon-Delalande Foundation, Grand

Prix for Science (joint recipient with Jonathan Seidman,PhD)(2007).

Norman C. SelbyNorman C. Selby is a Senior Managing Director at Perseusllc, a private equity firm and merchant bank(www.perseusllc.com) based in Washington DC and New

York City. Mr. Selby is responsible forPerseus’s strategy and investments inthe pharmaceutical, biotech and medicalproducts industries.

From 2001 to 2004, Mr. Selby wasPresident and CEO of TransFormPharmaceuticals, a specialty pharmaceu-tical company focused on innovation inthe form and formulation of drug com-pounds. During his tenure TransForm

grew from a start-up to a successful drug developmentcompany, signed major strategic alliances with Alza, Lillyand J & J, out-licensed two products and put its first propri-etary compound in the clinic. Johnson & Johnson acquiredTransForm for $230 million in cash in early 2005.

From 1997 to 2000, Mr. Selby was a Senior Officer atCitigroup/Citicorp. He joined as Executive Vice Presidentand head of Global Audit and Risk Review, and was a mem-ber of the Citicorp Management Committee. After themerger with Travelers, he became head of the ConsumerInternet Business, reporting to both John Reed and SandyWeill.

Prior to Citicorp, Mr. Selby was a Director (Senior Partner)in the New York office of McKinsey & Company, the interna-tional management consulting firm. In his 19 years atMcKinsey, Mr. Selby’s work was concentrated on strategyand organization issues for a variety of companies in thehealth care, consumer, communications and manufacturingindustries. Mr. Selby had several important leadership rolesat McKinsey, including head of the Firm’s GlobalPharmaceuticals Practice, head of the New York Office’sHealthcare and Consumer Industry Practices, and memberof the Firm’s Principals Committee. Mr. Selby also spent1984-1985 in McKinsey’s Dusseldorf Office.

Mr. Selby took a leave of absence from McKinsey from1987-1989 to serve as Chief Operating Officer of the NewYork Blood Center, the largest community blood organiza-tion in the country. During this time he led a major finan-cial and operational turnaround of the Blood Center.

Mr. Selby has a BA in Architecture from Yale College, andafter college worked at SCM Corporation and the BostonConsulting Group. Mr. Selby received an MBA withDistinction from the Harvard Graduate School of BusinessAdministration.

Mr. Selby is a member of the Board of Directors of


21

Millennium Pharmaceuticals (MLNM), and Nanobio, Inc. Heis also Chairman of Windhover Information, the leadingB2B publishing and information company in the pharma-ceutical, biotech and medical device industries. Its productsinclude publications like IN VIVO, Start-Up, RPM andMedtech Insight, 10+ major conferences, and the best database on business transactions and alliances in these indus-tries. In addition, Mr. Selby serves on the Board of Trusteesof the Central Park Conservancy, Memorial Sloan-KetteringCancer Center and the Ralph Lauren Center for Cancer Careand Prevention – all in New York City.

Ralph Snyderman, M.D.Dr. Snyderman is Chancellor Emeritus, Duke University andJames B. Duke Professor of Medicine in the Duke UniversitySchool of Medicine. He served as Chancellor for Health

Affairs and Dean of the School ofMedicine from 1989 to July 2004. Dr.Snyderman led the transition of thisexcellent medical center into an interna-tionally recognized leader of academicmedicine. During his tenure, the medicalschool and hospital achieved rankingamongst the nation’s best. Dr.Snyderman oversaw the development ofthe Duke University Health System, one

of the most successful integrated academic health systemsin the country, and served as its first President and ChiefExecutive Officer. Dr. Snyderman has played a leading rolein the conception and development of Prospective Care, anovel approach to personalized health and an evolvingmodel of national health care delivery. In 2004, after step-ping down as Chancellor, Dr. Snyderman founded Proventys,Inc., a company at the forefront of transforming health careinto a personalized and preventative approach through thedevelopment of high powered risk assessment and clinicaldecision support tools.

Dr. Snyderman accepted his first faculty appointment atDuke in 1972 and became chief of the Division ofRheumatology and Immunology in 1975 and, by 1984, hewas the Frederic M. Hanes Professor of Medicine andImmunology. His research contributed to the understandingof how white blood cells respond to chemical signals tomediate host defense or tissue damage. Dr. Snyderman isinternationally recognized for his contributions in inflamma-tion research. His bibliography exceeds 350 manuscripts aswell as numerous books. In 1987, Snyderman left Duke tojoin Genentech, Inc., the pioneering biomedical technologyfirm, as Senior Vice President for medical research anddevelopment and a member of its senior leadership team.While at Genentech, he led the development and licensingof several novel therapeutics.

A graduate of Washington College in Chestertown, Md.(1961), Snyderman received his M.D., magna cum laude, in1965 from the Downstate Medical Center of the StateUniversity of New York. He served his internship and resi-dency in medicine at Duke and later worked as a PublicHealth Officer doing research in immunology at the NIH(1967-72).

He is the recipient of numerous honors, including theCIBA GEIGY Award in 1992, the highest prize in inflamma-tion research, the 1993 Bonazinga Award for Excellence inLeukocyte Biology Research and awarded the AmericanCollege of Rheumatology Master designation in 2005.Snyderman was honored with the Lifetime AchievementAward from the Arthritis Foundation in 1997. In 1995,Downstate Medical Center of the State University of NewYork awarded him with their Distinguished AlumniAchievement Award, and in 1996, an Honorary Doctor ofScience degree. He was the recipient of the WashingtonCollege Distinguished Alumni Citation in 1996 and anHonorary Doctor of Science degree in 2004. In November2003, he was awarded the first Bravewell Leadership Awardfor outstanding achievements in the field of integrativemedicine.

Dr. Snyderman has been called upon by Congress, theInstitute of Medicine, the NIH, and national policy makersto contribute to the debate on health care reform, particu-larly his concepts concerning prospective care. He hasplayed a prominent role in the leadership of such importantnational organizations as the Association of AmericanPhysicians, the Institute of Medicine and the Association ofAmerican Medical Colleges. He is a member of the Instituteof Medicine and the American Academy of Arts & Sciences.He served as Chair of the AAMC in 2001-2002 andPresident of the Association of American Physicians in2003-2004.

Sharon F. Terry, M.A.Sharon is President and CEO of the Genetic Alliance, acoalition of over 600 disease specific advocacy organiza-tions working to increase capacity in advocacy organiza-

tions and to leverage the voices of themillions of individuals and familiesaffected by genetic conditions. She isthe founding Executive Director of PXEInternational, a research advocacyorganization for the genetic conditionpseudoxanthoma elasticum (PXE).Following the diagnosis of their twochildren with pseudoxanthoma elas-ticum (PXE) in 1994, Sharon, a former

college chaplain, and her husband, Patrick, founded andbuilt a dynamic organization that fosters ethical research

continued



22

and policies and provides support and information to mem-bers and the public.

She is at the forefront of consumer participation ingenetics research, services and policy and serves as a mem-ber of many of the major governmental advisory commit-tees on medical research, including the Food and DrugAdministration Cellular, Tissue and Gene Therapies AdvisoryCommittee and the Advisory Committee on HeritableDisorders and Genetic Diseases in Newborns and Children.She served as an Ethical Legal and Social ImplicationsResearch Advisor of NHGRI/NIH, the National Institute ofArthritis Musculoskeletal and Skin Diseases Council andcurrently is liaison to the National Advisory Council forHuman Genome Research. She is a member of the board ofdirectors of the Biotechnology Institute and on the advisoryboard of the Johns Hopkins Genetics and Public PolicyCenter funded by the Pew Charitable Trusts. She serves onthe boards of the Coalition for 21st Century Medicine, thePersonalized Medicine Coalition, DNA Direct, and theCenter for Information and Study on Clinical ResearchParticipation. She is the chair of the Coalition for GeneticFairness, composed of advocates, healthcare providers andindustry working to enact effective federal policy to prohibitgenetic information discrimination. She is also chair of theSocial Issues Committee of American Society of HumanGenetics. In 2005, she received an honorary doctorate from

IonaCollege for her work in community engagement andhaplotype mapping.

Ms. Terry is a co-founder of the Genetic Alliance Biobankand serves as president of its board. It is a centralized bio-logical and data [consent/clinical/environmental] repositorycatalyzing translational genomic research on rare geneticdiseases. The BioBank works in partnership with academicand industrial collaborators to develop novel diagnosticsand therapeutics to better understand and treat these dis-eases. Along with the other co-inventors of the gene associ-ated with PXE (ABCC6), she holds the patent for the inven-tion. She co-directs a 19-lab research consortium and man-ages 52 offices worldwide for PXE International.

Sharon feels strongly that advocates, working togetherand partnering with professionals and industry, can gener-ate the energy and mechanisms necessary to realize thepromise of biomedical research. Her work with the GeneticAlliance over the past few years has particularly focused ongenetic literacy, research protections, biosample reposito-ries, technology translation, genetic nondiscrimination,accessible services and youth issues. She has publishedwidely on these issues. Sharon is committed to facilitatingtechnical assistance to advocacy organizations, so that eachorganization benefits from the wisdom of the other.Sharon lives with Patrick and their two children inMaryland.


HARVARD MEDICAL SCHOOL-PARTNERS HEALTHCARE CENTER FOR GENETICS AND GENOMICS

To realize the promise of genetics and genomics in research and in medical practice,Harvard Medical School and Partners HealthCare System established the HarvardMedical School-Partners HealthCare Center for Genetics and Genomics (HPCGG) in2001. Its mission is to accelerate personalized medicine by discovering genetic knowl-edge and integrating it into clinical medicine. The availability of the human genomesequence and the many high throughput technologies that have been developed haveenabled an extraordinary growth in the identification of genes and of the specific geneticchanges that are responsible for human disease. Widespread use of genetic and genomicinformation will revolutionize medical practice. It is anticipated that genetic and genom-ic testing will become an integral part of diagnosis, prognosis and treatment of diseaseand in determining the appropriate drugs for individual patients.

HPCGG is accomplishing its mission through the following approaches:• Recruiting outstanding physicians and scientists• Offering genetic-based diagnostic testing and developing new tests in its

Laboratory for Molecular Medicine• Developing and implementing strategies for evaluating the clinical outcomes of

incorporating genetics into clinical practice• Developing an IT infrastructure to integrate genetic and genomic data into

clinical decision support systems• Caring for patients with genetic disorders• Training and educating physicians, scientists and the public

For more information about the Center, please visit www.hpcgg.org.

HARVARD BUSINESS SCHOOLHarvard Business School’s mission is to train business leaders in all industries.Healthcare, a $2 trillion industry, has become one of the school’s key priorities. TheHealthcare Initiative at HBS was launched in 2005 to bring together the extensiveresearch, thought leadership, and interest in the business and management of healthcarethat exists at HBS.

Healthcare research at HBS focuses on entrepreneurship, innovation and disruption.Faculty and students seek to understand and identify new products, services and deliverymethods that will help to reshape the industry. HBS believes this focus on “creativedestruction” will result in business models that offer the hope of improved outcomes,reduced costs, streamlined systems, and enhanced services.

Personalized medicine presents tremendous opportunities in healthcare and has garneredmuch attention at HBS. With its expertise in technology, commercialization, and busi-ness model development, HBS can play a critical role in the widespread adoption of per-sonalized medicine applications.

For more information about the HBS Healthcare Initiative, please visitwww.hbs.edu/healthcare.

Save the Date!Personalized Medicine

ConferenceNovember 13-14, 2008

Joseph B. Martin Conference Centerat Harvard Medical School

Boston, Massachusetts

HARVARD MEDICAL SCHOOL-PARTNERS HEALTHCARECENTER FOR GENETICS AND GENOMICS

77 Avenue Louis PasteurNRB Suite 250

Boston, MA 02115

[email protected]

personalized medicinepersonalizedmedicine.partners.org/assets/documents... · personalized...

Documents